PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Warfarin (also called Coumadin®) is an anticoagulant drug (blood thinner) given to patients
to help prevent blood clots from forming or to help prevent the growth of an existing blood
clot. The purpose of this study is to collect information on a possible method used to
determine the best warfarin dose for people before they start warfarin. This study will focus
on finding out if a person's stable dose can be better predicted by using a new approach
(called "pharmacogenetic-guided dosing") compared to the current warfarin dosing method. The
pharmacogenetic-guided dosing method (the new warfarin dosing method) will use a person's
specific health and genetic information to calculate a patient's warfarin dose at the
beginning of warfarin treatment. The hope is that through this research, we may someday be
able to use an individual's genetic information to guide the selection of their specific
warfarin dose at the beginning of treatment, leading to precise warfarin dosing and less need
for the current trial and error process.